During the 27th Congress of the International Society of Heterocyclic Chemistry in Kyoto, Japan, Dale Boger, PhD, received the E.C. Taylor Senior Award in Heterocyclic Chemistry. Boger is the Richard and Alice Cramer Professor of Chemistry and focuses his research on synthetic organic and bioorganic chemistry. Discoveries in his lab have led to an experimental cancer vaccine that boosts the immune system’s ability to fight cancers and a structurally modified form of vancomycin that makes the antibiotic 25,000 times more potent. Along with Scripps Research professor Ben Cravatt, PhD, Boger founded a clinical-stage biopharmaceutical company, Abide Therapeutics, that uses a unique chemo-proteomic platform to identify new classes of drugs for a range of clinical disorders. Abide was acquired by Danish pharmaceutical firm H. Lundbeck A/S in May.